MedTech Acquisition Corporation (MTAC) Stock

About MedTech Acquisition Corporation

MedTech Acquisition Corporation currently has no significant active business operations. The firm's stated intention is to pursue and finalize a business combination — which could involve a merger, stock exchange, asset acquisition, or other forms of corporate restructuring — with one or more enterprises in the U.S. healthcare industry. Established in 2020, its corporate base is situated in Greenwich, Connecticut.

MedTech Acquisition Corporation is headquartered in US.

MedTech Acquisition Corporation (MTAC) stock trades at $11.34 with a market capitalization of $83.86M. The stock is valued at a negative price-to-earnings (P/E) ratio of -8.66, reflecting a net loss over the last twelve months, price-to-book of 95.11, price-to-sales of 1.86. Over the past 52 weeks the stock has ranged between $8.43 and $12.83, and currently trades 11.6% below its 52-week high.

On profitability, MedTech Acquisition Corporation generates a return on equity (ROE) of 540.49%, above the typical market range of roughly 12-15%, return on capital employed of -59.50%, an operating margin of -67.68%, a net profit margin of -123.59%.